US healthcare review: pandemic, politics, pricing, and the payer landscape

In this market access update, Emily explores the shifting dynamics of US healthcare in the post-pandemic era and highlights the three most potentially impactful reforms for biopharma: an external pricing model, proposed changes to Medicare Part D, and the expansion of Medicaid. The US payer environment is once again mired in a rinse-repeat cycle of challenge and change – with significant ramifications for global biopharma.

Read the source article at PRMA Consulting
2021-09-21 11:19:11